Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

STOK - Stoke Therapeutics Inc Stock Price, Fair Value and News

$30.93+1.12 (+3.76%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

STOK Price Action

Last 7 days

-0.9%

Last 30 days

18.5%

Last 90 days

57.6%

Trailing 12 Months

170.6%

STOK RSI Chart

MarAprMayJunJulAugSepOctNovDec102030405060708090100

STOK Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

43.55

Price/Sales (Trailing)

8.59

EV/EBITDA

63.21

Price/Free Cashflow

33.74

STOK Price/Sales (Trailing)

202320242025020406080

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

STOK Fundamentals

STOK Revenue

Revenue (TTM)

205.6M

Rev. Growth (Yr)

117.25%

Rev. Growth (Qtr)

-23.05%

202320242025050M100M150M200M

STOK Earnings

Earnings (TTM)

40.6M

Earnings Growth (Yr)

-45.09%

Earnings Growth (Qtr)

-63.3%

2019202020212022202320242025-100M-50M050M

STOK Profitability

EBT Margin

11.97%

Return on Equity

13.17%

Return on Assets

11.26%

Free Cashflow Yield

2.96%

STOK Investor Care

Shares Dilution (1Y)

7.84%

Diluted EPS (TTM)

0.69

STOK Alerts

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2023AprJulOct2024AprJulOct2025AprJul020M40M60M80M100M120M140M160M180M200M220M
Net sales
YearQ1Q2Q3Q4
2025190.9M199.9M205.6M0
202412.0M15.2M16.7M36.6M
202314.6M12.6M10.7M8.8M
202200012.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
 CEO
 WEBSITEstoketherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES117

Stoke Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Stoke Therapeutics Inc? What does STOK stand for in stocks?

STOK is the stock ticker symbol of Stoke Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Stoke Therapeutics Inc (STOK)?

As of Wed Dec 03 2025, market cap of Stoke Therapeutics Inc is 1.77 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STOK stock?

You can check STOK's fair value in chart for subscribers.

Is Stoke Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether STOK is over valued or under valued. Whether Stoke Therapeutics Inc is cheap or expensive depends on the assumptions which impact Stoke Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STOK.

What is Stoke Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, STOK's PE ratio (Price to Earnings) is 43.55 and Price to Sales (PS) ratio is 8.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STOK PE ratio will change depending on the future growth rate expectations of investors.